Walleye Capital
RAPT

Walleye Capital’s RAPT Therapeutics RAPT Stock Holding History

Walleye Capital’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,645
Closed -$203K – 5425
2024
Q3 		$203K Sell
12,645
-1,829
-13% -$37K ﹤0.01% 3995
2024
Q2 		$353K Buy
14,474
+4,797
+50% +$222K ﹤0.01% 3832
2024
Q1 		$695K Buy
+9,677
New +$1.35M ﹤0.01% 2916
2023
Q2 		– Sell
-4,617
Closed -$678K – 4797
2023
Q1 		$678K Sell
4,617
-30,935
-87% -$6.26M 0.01% 1439
2022
Q4 		$5.63M Buy
+35,552
New +$5.69M 0.1% 242
2022
Q3 		– Sell
-4,790
Closed -$699K – 3481
2022
Q2 		$699K Sell
4,790
-3,460
-42% -$461K 0.02% 829
2022
Q1 		$1.45M Buy
8,250
+1,884
+30% +$356K 0.04% 470
2021
Q4 		$1.87M Sell
6,366
-5,037
-44% -$1.35M 0.06% 346
2021
Q3 		$2.83K Buy
11,403
+897
+9% +$237K 0.08% 171
2021
Q2 		$2.67K Buy
+10,506
New +$1.96M 0.09% 189

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Capital's RAPT Position: Q4 2024 in Review

Walleye Capital sold out of RAPT Therapeutics (RAPT) in Q4 2024, closing a stake of 12,645 shares — an estimated $203K sold.

Walleye Capital first reported a position in RAPT in Q2 2021 and held it in 10 quarters. The position peaked at $5.63M in Q4 2022. 91 funds tracked by Wall St. Rank hold RAPT as of Q4 2024.

  • Walleye Capital reported no remaining RAPT Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 12,645 RAPT Therapeutics shares in Q4 2024, an estimated $203K.
  • Walleye Capital first reported a position in RAPT Therapeutics in Q2 2021 and held it in 10 quarters.
  • Walleye Capital's RAPT Therapeutics position peaked at $5.63M in Q4 2022.
  • 91 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.